"I've been on semaglutide for two months and I've barely lost anything. Should I just quit?" It is one of the most common questions people ask about GLP-1 medications, and it usually comes with a sense of personal failure, especially when a coworker or neighbor saw a very different result on the same drug. The honest answer is that response to these medications varies widely from person to person, and a slow start does not automatically mean the drug has failed you. This article walks through what the research actually shows about why GLP-1 response differs, what the evidence does not yet support, and how to find safe, legal care. As an independent resource, the Peptide Foundation sells nothing and prescribes nothing. The goal here is to help you read the evidence clearly.
Why GLP-1 Response Varies So Much Between People
GLP-1 receptor agonists do not appear to act identically in everyone. Research into genetic predictors of GLP-1 response has been reported in the scientific literature, with studies identifying genomic variants near genes involved in receptor signaling, appetite regulation, and metabolic rate that appear to correlate with weight-loss outcomes and side-effect burden. Some variants may increase receptor sensitivity; others may blunt the response so a standard dose produces less effect than expected. This is an area of active investigation, and the findings are directional rather than settled. They may help explain, mechanistically, why one person tolerates a medication easily while another struggles early on, but they are not yet a clinical test you can order.
Not All GLP-1 Drugs Work the Same Way
It also helps to understand that "GLP-1 medication" is not one uniform thing. Semaglutide acts primarily at the GLP-1 receptor. Tirzepatide adds a second mechanism by also activating the GIP receptor. Newer investigational agents such as retatrutide engage a third pathway (the glucagon receptor) in early-phase trials. Because these drugs engage different combinations of pathways, a person who responds modestly to one may respond differently to another. The mechanisms are related but distinct, which is one reason switching agents is sometimes discussed with a clinician as a next step rather than abandoning the class entirely.
What the Research Actually Shows
Published trial data give a sense of what these drugs have done in controlled studies, though individual results vary and none of this predicts your personal response. In a 68-week randomized trial, once-weekly semaglutide 2.4 mg was associated with a mean body-weight reduction of about 14.9 percent versus 2.4 percent for placebo. In tirzepatide trials, mean weight reductions ranged from roughly 15 to 21 percent across doses over 72 weeks versus about 3 percent for placebo. Retatrutide, which remains investigational and is not FDA-approved for weight loss, was associated with dose-dependent reductions in a phase-2 obesity trial. These are averages from selected trial populations. They describe what was studied, not what will happen for any one person.
It is equally important to be honest about the limits of the evidence. Routine genetic testing to predict which GLP-1 drug will work for a given person is not standard of care. There is no validated, commercially standardized panel you can order today that returns a clear "this drug will work for you" answer. What the research is building is a framework for understanding why responses differ, not a finished tool. Claims that a specific test or protocol guarantees results should be treated with skepticism.
Before Concluding It Isn't Working
A slow start is frequently mistaken for treatment failure. GLP-1 prescribing commonly involves a gradual titration phase that can last many weeks, intended to limit side effects. People who are still early in that phase may be comparing themselves to others who are already at a higher maintenance level, which is not a fair comparison. Duration and where you are in the process both matter, and these are questions best worked through with a prescribing clinician rather than settled alone.
Weight physiology is genuinely complex, and factors beyond the GLP-1 pathway can influence what you see on the scale. Insulin resistance, thyroid function, cortisol, sleep, and other medications can all play a role. Because of this, a modest response to one agent does not by itself define someone as a "non-responder" to the whole class. These are diagnostic questions for a qualified clinician, not conclusions to reach from a single data point.
What the Evidence Says About Stopping
The evidence here is worth understanding clearly. GLP-1 receptor agonists influence appetite and metabolic signaling while they are being taken, but the research does not suggest they permanently reprogram baseline physiology. In a randomized trial where people either continued semaglutide or switched to placebo, those who continued tended to sustain their results while those switched to placebo tended to regain weight. Longer-term follow-up studies have described weight loss maintained while treatment continued. This is often framed as consistent with a chronic-disease model of obesity rather than a personal failure, and it is one reason many clinicians describe these medications as long-term. Any decision to continue, taper, or stop is one to make with a clinician, not unilaterally.
How to Find Safe, Legal Treatment
If your medication does not seem to be working, the next step is a structured clinical review, not a purchase from an unregulated source. That means a licensed prescriber who dispenses through a legitimate pharmacy, reviews your response at regular intervals, and can discuss options with you. To compare options, see the independent provider directory, and read how we rate to understand what we look for. If you have broader questions about safety and legality, the FAQ is a good starting point.
The Bottom Line
The idea that GLP-1 medications either work dramatically or not at all is a false binary. Response varies for reasons researchers are still mapping, and a modest early result is a signal to ask questions, not necessarily a verdict. Nothing here is medical advice, a dosing recommendation, or a promise of any outcome. It is a starting point for a more informed conversation with a qualified, licensed clinician who can look at your full picture.